Patent: 10,383,954
✉ Email this page to a colleague
Summary for Patent: 10,383,954
Title: | Methods of inducing responsiveness to anti-angiogenic agent |
Abstract: | The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist. |
Inventor(s): | Leubitz; Andrea Rachel (Efrat, IL), Sher; Naamit (Rechovot, IL), Feige; Erez (Hemed, IL), Breitbart; Eyal (Hashmonaim, IL) |
Assignee: | Vascular Biogenics Ltd. (Modi\'in, IL) |
Application Number: | 15/607,083 |
Patent Claims: | see list of patent claims |
Details for Patent 10,383,954
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2033-02-04 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 06/30/2006 | ⤷ Try a Trial | 2033-02-04 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 08/10/2012 | ⤷ Try a Trial | 2033-02-04 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 10/13/2016 | ⤷ Try a Trial | 2033-02-04 |
Genentech, Inc. | LUCENTIS | ranibizumab | Injection | 125156 | 03/20/2018 | ⤷ Try a Trial | 2033-02-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |